tradingkey.logo
tradingkey.logo
검색

ANI Pharmaceuticals Inc

ANIP
관심 목록에 추가
78.010USD
-1.570-1.97%
종가 05/15, 16:00ET시세는 15분 지연됩니다
1.75B시가총액
18.96P/E TTM

ANI Pharmaceuticals Inc

78.010
-1.570-1.97%

자세한 내용은 ANI Pharmaceuticals Inc 회사

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc 정보

종목 코드 ANIP
회사 이름ANI Pharmaceuticals Inc
상장일May 04, 2000
CEOLalwani (Nikhil Suresh)
직원 수897
유형Ordinary Share
회계 연도 종료May 04
주소210 Main Street West
도시BAUDETTE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호56623
전화12186343500
웹사이트https://www.anipharmaceuticals.com/
종목 코드 ANIP
상장일May 04, 2000
CEOLalwani (Nikhil Suresh)

ANI Pharmaceuticals Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.85K
-12.61%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
--
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%

수익 분석

통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%
지역별USD
이름
수익
비율
United States
852.44M
96.50%
International
30.92M
3.50%
사업별
지역별
사업별USD
이름
수익
비율
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%

주식 보유 통계

마지막 업데이트: Sun, May 10
마지막 업데이트: Sun, May 10
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
기타
75.58%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
기타
75.58%
주주 유형
주주
비율
Investment Advisor
42.89%
Investment Advisor/Hedge Fund
23.64%
Hedge Fund
20.43%
Research Firm
6.41%
Individual Investor
5.68%
Private Equity
4.46%
Pension Fund
2.51%
Corporation
1.92%
Bank and Trust
1.50%

기관 주식 보유

마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
555
23.15M
101.74%
+57.73K
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
2.45M
10.91%
+103.61K
+4.42%
Dec 31, 2025
Meridian Venture Partners
1.01M
4.53%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
727.20K
3.24%
+15.50K
+2.18%
Dec 31, 2025
Millennium Management LLC
539.66K
2.41%
+474.42K
+727.14%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
487.67K
2.18%
-17.76K
-3.51%
Dec 31, 2025
Soleus Capital Management, L.P.
486.24K
2.17%
+146.00K
+42.91%
Dec 31, 2025
Tang Capital Management, LLC
481.44K
2.15%
+163.94K
+51.63%
Dec 31, 2025
Deep Track Capital LP
477.68K
2.13%
+27.68K
+6.15%
Dec 31, 2025
더 보기

관련 ETF

마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
더 보기
Invesco Pharmaceuticals ETF
비율2.63%
State Street SPDR S&P Pharmaceuticals ETF
비율2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
비율1.63%
Innovator IBD Breakout Opportunities ETF
비율1.38%
Innovator IBD 50 Fund ETF
비율1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
비율0.98%
Invesco S&P SmallCap Health Care ETF
비율0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
비율0.92%
First Trust Small Cap Growth AlphaDEX Fund
비율0.67%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
KeyAI